FONR
FONAR Corporation14.35
-0.40-2.71%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
90.35MP/E (TTM)
12.93Basic EPS (TTM)
1.11Dividend Yield
0%Recent Filings
8-K
Q2 profits rise amid merger
FONAR posted Q2 fiscal 2026 net revenues up 2% to $25.5M and net income up 15% to $2.5M versus year ago, while six-month net income dipped 16% to $5.2M. Cash fell 6% to $53.0M. Scan volumes hit third-highest ever, boosted by new high-field MRI. Merger deal hiked offer to $19/share; stockholder vote pending.
10-Q
Q2 FY2026 results
FONAR posted Q2 FY2026 revenue of $25.5M, up 2.4% y/y from $25.0M, with operating income climbing 23.3% y/y to $3.0M on steady costs; diluted EPS held at $0.31 (6,296 diluted shares). Management fees drove gains while patient fees dipped amid Florida no-fault reliance (~63% of revenues). YTD revenue rose 3.3% y/y to $51.6M yet operating income fell 12.1% y/y to $6.2M as expenses outpaced. Cash sits at $53.0M after $1.9M operating cash less $2.5M noncontrolling distributions; FCF not disclosed in the 10-Q. Proposed going-private merger announced Dec 23, 2025 faces Delaware Chancery litigation. Scans ticked up sans hurricanes. Tort reform squeezes reimbursements.
8-K
FONAR agrees to go private
FONAR signed a merger agreement on December 23, 2025, to go private via acquisition by an LLC led by CEO Timothy Damadian and executives, offering $19.00 per common/Class B share, $6.34 per Class C share, and $10.50 per Class A preferred. Backed by $35M bank debt, $10M additional debt, and $45M equity, closing awaits stockholder approval by March 12, 2026, and delisting from Nasdaq. Management takes control.
8-K
Revenues up, profits down
FONAR posted Q1 fiscal 2026 results on November 10, with net revenues up 4% to $26.0 million, driven by 3% HMCA growth to $23.5 million and 14% FONAR segment rise to $2.5 million. Yet operating income plunged 30% to $3.2 million as S,G&A spiked 33% to $6.8 million. Negotiations drag on a CEO-led going-private bid. Scan volumes hit second-highest ever.
10-Q
Q1 FY2026 results
FONAR posted Q1 FY2026 revenue of $26.0M, up 4.3% y/y from $25.0M, driven by management fees rising to $16.0M from $15.3M while patient fees edged to $7.6M from $7.5M. Operating income dipped to $3.2M from $4.6M as SG&A jumped 33% to $6.8M on take-private costs and IT upgrades, yet diagnostic centers delivered $4.4M operating income on 55,106 scans. Diluted EPS held at $0.34 on 6,296 diluted shares, matching two-class math. Cash sits ample at $54.3M with operating cash flow of $1.7M less $1.9M capex. Negotiations drag on going-private bid. Reimbursement cuts pinch margins.
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BRKR
Bruker Corporation
44.96-0.71
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
FLGT
Fulgent Genetics, Inc.
27.16+0.24
ICLR
ICON plc
182.45-1.92
ILMN
Illumina, Inc.
131.56-3.36
NDRA
ENDRA Life Sciences Inc.
4.94-0.37
RDNT
RadNet, Inc.
71.22-1.35
TMO
Thermo Fisher Scientific Inc
570.16-5.75